The biostatistics workgroup on the FINAL RULE

Janet Wittes
Statistics Collaborative, Inc.

22-May-12
Participants

- Aloka Chakravarty
- Christy Chuang-Stein
- Brenda Crowe
- Dave DeMets
- Achim Guettner
- David Hall
- Qi Jiang
- Kerry Lee
- Devan Mehrotra
- Robert O’Neill
- Steve Snapinn
- Janet Wittes
- Amy Xia
FDA 15-day reports: Investigational products

• Former rule – reported by investigator
  ▫ Serious
  ▫ Unexpected (not in the investigator brochure)
  ▫ Associated with study drug
    • i.e., investigator could not rule out association

• Sent to FDA/IRBs/ECs/DSMBs/Investigators
The problem: FDA 15-day reports

- Many were sent....
- Few were read...
- Fewer were interpretable
The change: FDA 15-day reports

- **Properties**
  - **Serious**
  - **Unexpected (not in the investigators brochure)**
  - “Associated with study drug”
    - Some evidence of a causal relationship
    - Determined by investigator or Sponsor
The challenge: Want to separate wheat from chaff

Send fewer reports
But don’t miss signals
The Safety Planning, Evaluation and Reporting Team (aka SPERT)

- Two influential papers in Clinical Trials
  Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development.

Xia et al. (2011) 8:175-82.
Planning and core analyses for periodic aggregate safety data reviews.
Our charge

- How to quantify harms
- How to assess risk (not vs. benefit)
- So Sponsors will know what to report in 15 days
Statistical topics: 15 day reporting

- How to set trigger (threshold) for reporting
  - New events
  - Increased frequency of events
- Should we worry about blinding (if so, why?)
- Most of the issues not statistical
We are looking for events to report

- Not necessarily a known harm
- Something that is a potentially a harm
  - A signal
  - “Reasonable possibility” of being real: NEW
    - Small studies – overreporting not a burden
    - Large studies (e.g., CV studies) – want specificity
Classes of events

A. Single occurrence of event known to be strongly associated with drug exposure (Stevens-Johnson Syndrome, hepatic injury...)

B. A few (1? 2? 3?) events not commonly associated with drug exposure but otherwise uncommon in the population exposed to the drug

C. Common events that occur more frequently than expected in the treatment group
A. Rare but associated with drugs

- Not a statistical issue
B. A few surprising events

- Examples
  - Tendon rupture in any population
  - Myocardial infarction in young women

- When to report
  - Small trials: each one
  - Large trials: ??
C. Aggregate of specific events

- This is the most difficult – no one case a surprise
- Study of the elderly – strokes and MIs
- Study in kids - infections
What are the issues?

• Who is looking at the data?
  ▫ To whom do they report?
• How do we deal with coding (e.g., MedDRA)?
  ▫ Lumping or splitting
  ▫ What do verbatim terms mean?
    • Huge cultural differences in symptoms recognized and called
    • Remember “hysteria”?
Issues, continued

• Who is looking at the data?
• Do we lump or split?
• How do we look at ongoing trials?
• How do we look at completed trials?
B. Analysis of a Single Type of Outcome Based on Observing Increased Frequency Relative to Expectation

<table>
<thead>
<tr>
<th>Is Imbalance (IMB) Clear?</th>
<th>Yes: No IMB</th>
<th>Unclear</th>
<th>Yes: IMB</th>
</tr>
</thead>
<tbody>
<tr>
<td>DO NOT REPORT</td>
<td></td>
<td>REPORT IF...</td>
<td>If CI excludes 0 AND Rel Risk&gt;3 AND Lumping similar events doesn’t make signal disappear THEN imbalance CLEAR</td>
</tr>
<tr>
<td></td>
<td>Other safety outcomes support causality</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mech of action and labs support causality</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Investigators need info to manage patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Info might affect pt’s willingness to continue</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pooling similar outcomes strengthens signal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Even if potentially fatal or disabling</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OTHERWISE: DON’T REPORT</td>
<td></td>
<td>REPORT</td>
</tr>
</tbody>
</table>
But of course there are problems..

- Multiplicity
- Rel risk >3?
- What if it almost excludes 0?
- Answer: we are not looking for proof, just reasonable probability, so REPORT
C. Analysis of a Single Type of Outcome Based on Observing Increased Frequency Relative to Control

<table>
<thead>
<tr>
<th>Is Imbalance (IMB) Clear?</th>
<th>Yes: No IMB</th>
<th>Unclear</th>
<th>Yes: IMB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DO NOT REPORT</strong></td>
<td>REPORT IF...</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other safety outcomes support causality</td>
<td></td>
<td></td>
<td>80% CI exclude 0 AND Rel Risk &gt; 2</td>
</tr>
<tr>
<td>Mech of action and labs support causality</td>
<td></td>
<td></td>
<td>AND Lumping similar events doesn’t make signal disappear</td>
</tr>
<tr>
<td>Investigators need info to manage patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Info might affect pt’s willingness to continue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pooling similar outcomes strengthens signal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even if potentially fatal or disabling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OTHERWISE: DON’T REPORT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Investigators need info to manage patient
Info might affect pt’s willingness to continue
Pooling similar outcomes strengthens signal
But of course there are problems..

- Multiplicity
- What if the control is not placebo?
  - Oral anti-diabetic with rosiglitazone as a control
  - Omega-3 fatty acid with other oils as control
- Answer: we are not looking for proof, just reasonable probability, so go to B’s tree
How we learned to stop worrying and love multiplicity*

- Recall, we are detecting signals
- Trying to cut out a host of false signals
- But a few false ones are acceptable

*With thanks to Dr. Strangelove
Ongoing struggles

- Role of the DMC
  - DMCs: traditionally thought about risk vs benefit
  - Cautious about reporting new associated events
- Role of internal pharmacovigilance group
- Who should be unblinded?
- What does meta-analysis tell us
Appeal to the FDA

- FDA review team must buy into the Final Rule
- FDA should develop a regulatory guidance
- Need harmonization with other reg bodies
Conclusion

• Stay tuned....more coming in July.....